Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancers Dosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumors MP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026 Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D.ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...

The year 2025 was the first full year in the operating history of EfTEN United Property Fund in which the Fund did not make new larger investments, and the financial results reflected the full performance of the existing portfolio. During the year, the Fund generated its highest net profit to date, increasing 2.2 times compared to 2024. In 2025, EfTEN United Property Fund earned a net profit of 3.57 million euros (2024: 1.62 million euros), representing approximately 14% of the Fund’s invested capital and around 17% of its market capitalisation. The Fund’s revenues increased from 1.82 million euros to 3.78 million euros year-on-year, and in 2025 the Fund made distributions to investors in an amount exceeding 9% of its market capitalisation.  The Fund’s financial performance was supported primarily by the improved profitability of the Uus-Järveküla residential...

CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group) DIJON, France – February 2, 2026 (7:15 a.m. CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharmaceutical company that develops products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology. CROSSJECT is in the advanced stages of developing and registering ZEPIZURE®, an injectable for the treatment of epileptic seizures, and announces the initiation of coverage of its stock by Portzamparc (BNP Paribas Group). Coverage of CROSSJECT shares has been initiated with a study entitled “The needles will soon be nothing more than a bad memory” which includes a “Strong Buy” recommendation with a target price of €4.50. CROSSJECT shares are now covered by:– Alpha Value– Invest Securities–...

Mowi ASA hereby invites you to the presentation of the results for the fourth quarter 2025 at The Salmon, Strandpromenaden 11, 0252 Oslo, Norway. The results will be presented in English through a live webcast followed by a Q&A session. Participants will have the opportunity to submit questions online throughout the webcast session. The webcast will be available on http://www.mowi.com/investors/reports/ A recording of the webcast will be made available on our website immediately afterwards. Please note that the quarterly report and presentation will be published at 06:30 (CET). This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Advancing one of the Largest Primary Silver Assets in the United States VANCOUVER, British Columbia, Feb. 02, 2026 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo Silver” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF) is pleased to announce that it has received acceptance into the U.S. Defense Industrial Base Consortium (“DIBC”), a U.S. Department of Defense-supported initiative designed to support collaboration across industry, academia, and government in advancing solutions relevant to U.S. defense and national security priorities. The DIBC focuses on strategic and critical materials and technologies essential to U.S. national security, including initiatives to improve the resilience and security of domestic critical mineral supply chains that support defense and industrial applications1. Apollo Silver’s U.S.-based...

Shareholders will receive shares in project buyer Bellavista Resources Ltd, giving them ongoing exposure to the assets and their substantial exploration upside while FireFly targets ongoing growth at its Green Bay Copper-Gold ProjectFireFly has agreed to sell its Ontario Gold Assets, comprising its 70% interest in the Pickle Crow Project and 100% of the Sioux Lookout Project to ASX-listed Bellavista Resources Ltd (ASX: BVR) for total scrip consideration with a deemed aggregate value of up to A$86.1m1 FireFly will receive upfront consideration of 60 million Bellavista shares (A$47.4m1) and contingent consideration of 50 million Bellavista performance rights (A$38.7m2) Subject to shareholder approval, FireFly to undertake an in-specie distribution of the ~A$47.4m upfront Bellavista consideration shares, which is expected to comprise...

MELBOURNE, Australia, Feb. 01, 2026 (GLOBE NEWSWIRE) — BHP has selected 10 early-stage exploration and technology companies for the 2026 BHP Xplor program, marking the largest cohort since the program began and its fourth year of operation. The 2026 cohort brings together junior exploration companies, geoscience organisations, and technology teams that collectively span the discovery system. It reflects a more connected approach to early-stage exploration, where geological insight, data, and emerging technologies increasingly intersect, and where collaboration across disciplines is becoming central to how discovery evolves. As exploration moves into more remote and geologically complex environments, this intersection of expertise is opening up new possibilities for how mineral systems are understood, tested, and advanced at the...

Paris, February 1st, 2026, 22:45pm PRESS RELEASE Eramet: Announcement from the Board of Directors regarding the management of the Group The Board of Directors of Eramet, meeting on Sunday, February 1st, has decided to terminate the mandate of Mr. Paulo Castellari as Chief Executive Officer, due to divergences on operating methods. The termination of his mandate as Chief Executive Officer takes effect this evening. The Board of Directors has appointed its Chairwoman, Ms. Christel Bories, as Chief Executive Officer of the Group on an interim basis, pending the completion of a process to select a new Chief Executive Officer. Upon the appointment of the new CEO, the roles of Chair and Chief Executive Officer will once again be separated. The Board of Directors thanks Paulo Castellari for his efforts and reaffirms its support for the teams,...

Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The FDA raised an issue with the potential for underexposure in lower weight pediatric patients. As a result, the FDA has requested additional pediatric pharmacokinetic data to reassess the proposed pediatric doses and confirm that children in the lower weight dose groups can achieve exposure levels comparable to the approved adult and adolescent regimen. The...